Paul Manning

Paul Manning

investor United States

Paul Manning is a prominent investor in AveXis, the biotech company responsible for developing Zolgensma, the world’s most expensive drug. His significant financial backing and involvement in the startup have raised questions about the motivations behind high drug prices and the commercialization of gene therapies.

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
0
Power
0$
Sentiment
0.00
Countries Mentioned

No country-level mention data available.

Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

United States United States: Paul Manning, the company’s chief executive at Sensient Technologies Corp., discussed the supply issues related to natural dyes. 5

Marty Makary Monica Giusti Melanie Benesh Renee Leber Marion Nestle
CNN: These natural food dyes could replace artificial colorants

New Zealand New Zealand: Liquidator Paul Manning told the Bay of Plenty Times the investigation into a potential claim against a previous funder related to a government funder. 6

Thomas Rodewald Donna Gardiner Sandra Conchie
The New Zealand Herald – country’s largest newspaper, est. 1863: Tauranga’s Te Tuinga Whānau Support Services Trust in liquidation months after closing

United States United States: Paul Manning was a major investor in AveXis and made significant profits from the company's acquisition by Novartis. 5

Vincent Gaynor Catherine Gaynor Sophia Gaynor Brian Kaspar John Carbona James Love David Mitchell Hailey Weihs Eamon Kelly Sean P Nolan
CNN: What a $2 million per dose gene therapy reveals about drug pricing